Drawing for FLEXISEQ

USPTO serial 79115213

FLEXISEQ

Reviewed by CopyMark Law Group

Reg. 4437885Status 709
Filing date
Status date
Registration date
Nov 26, 2013
Examiner
BUONGIORNO, CHRISTOPHER L
Law office
TMEG LAW OFFICE 101

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with FLEXISEQ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Roberta S. Bren

Roberta S. Bren MUNCY, GEISSLER, OLDS & LOWE, P.C.4000 Legato Road, Suite 310Fairfax, VA 22033UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001[ Surfactants and lipids for use in the manufacture of personal care products, chemical products for in vitro and in vivo use in research and development ]SECTION 71 - CANCELLED—
005Pharmaceutical preparations and substances for the treatment of pain and inflammation; [ veterinary and sanitary preparations and substances for the treatment of pain and inflammation; chemical preparations for pharmaceutical purposes, namely, for the treatment of pain and inflammation; diagnostic preparations and substances for medical purposes for in vivo use; pharmaceuticals for treating osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparation for medical and veterinary use; topical and parenteral preparations of vesicles, namely, liquids or gels for the treatment of pain and inflammation; chemical preparations for the treatment of pain and inflammation in the form of vesicles for medical and veterinary purposes; pharmaceutical preparations being chemical membranes and chemical aggregates for medical and veterinary purposes; pharmaceutical preparations of arachidonic acids for the treatment of pain and inflammation; dispersions and dry preparations of liposomal active substance carriers for use as a pharmaceutical, cosmetic substance carrier, in the nature of a liquid, gel, cream, lotion or lipid; cosmeceutical preparations in the nature of medicated cosmetics; local anesthetics; steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines; immunotherapeutic vaccines; topical and parenteral lipids for use in the treatment of pain and inflammation; ] medicated creams, medicated dispersions, medicated lotions, medicated ointments, medicated gels [, medicated solutions, medicated sprays, medicated lacquers and pharmaceutical solutions which form a film on the skin for the treatment of pain and inflammation; surfactants for medical use in the treatment of or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrhoeic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea, hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, Alzheimer's disease, gout, macular degeneration, age-related macular degeneration, fungal infection and disorders related to fatty acid deficiencies ]SECTION 71 - CANCELLED—
010[ Medical devices in the nature of a carrier with nanostructures which cross through the skin for the treatment of pain and inflammation associated with osteoarthritis; ] molecular filtering devices for medical use, namely, a liquid or gel as a drug delivery device which filters through the skin and has a physical therapeutic effect at the point of complaint; medical [, veterinary ] and surgical devices, namely, a medical device which acts as a drug delivery system in the nature of non-pharmaceutical nanostructures that migrate through the skin and have a physical therapeutic effect at the point of complaint [ ; inhalers for medical purposes sold empty; injection devices, namely, medical syringes and medical fluid injectors; medical instruments and devices for the administration of pain relief therapy and prophylaxis preparations and substances ]SECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 6, 2026INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Mar 6, 2026C71TCANCELLED SECTION 71—
Nov 26, 2022REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Dec 30, 2021RNWLINTERNATIONAL REGISTRATION RENEWED—
Nov 7, 2020INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Oct 1, 2020INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Oct 1, 2020INPCINVALIDATION PROCESSED—
Sep 8, 2020INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jan 8, 2020NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Jan 8, 2020C75PREGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.—
Jan 3, 2020NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 9, 2019APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 4, 2019ES75TEAS SECTION 71 & 15 RECEIVED—
Aug 9, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 26, 2018REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Mar 14, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 14, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 13, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 27, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 27, 2014FIMPFINAL DISPOSITION PROCESSED—
Feb 26, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 26, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 15, 2013GPNXNOTIFICATION PROCESSED BY IB—
Sep 10, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 10, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 28, 2013OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 28, 2013OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Aug 21, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 7, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 7, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 15, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 15, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 15, 2013ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Mar 11, 2013GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Mar 11, 2013GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 11, 2013CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 14, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 14, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 8, 2013ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 8, 2013REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 8, 2013ALIEASSIGNED TO LIE—
Feb 8, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 1, 2012RFNTREFUSAL PROCESSED BY IB—
Aug 15, 2012RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 15, 2012RFRRREFUSAL PROCESSED BY MPU—
Aug 14, 2012RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 14, 2012MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 13, 2012CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 8, 2012DOCKASSIGNED TO EXAMINER—
Aug 8, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 2, 2012REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance